TCGA-CU-A0YO-01A-11R-A10U-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 4.894875164
- os_event
- true
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.550
- INFLAMMATORY_RESPONSE+0.490
- ESTROGEN_RESPONSE_EARLY+0.460
- KRAS_SIGNALING_UP+0.460
- ALLOGRAFT_REJECTION+0.430
- IL6_JAK_STAT3_SIGNALING+0.390
- ANGIOGENESIS+0.380
- UV_RESPONSE_DN+0.380
- APICAL_SURFACE+0.360
- HEDGEHOG_SIGNALING+0.360
Top 10 suppressed
- E2F_TARGETS-0.600
- MYC_TARGETS_V1-0.550
- G2M_CHECKPOINT-0.530
- MYC_TARGETS_V2-0.520
- DNA_REPAIR-0.500
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.390
- OXIDATIVE_PHOSPHORYLATION-0.380
- UNFOLDED_PROTEIN_RESPONSE-0.380
- MTORC1_SIGNALING-0.320
- MITOTIC_SPINDLE-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-38-7271-01A-11R-2039-07 | — | cohortMD2 | 0.953 |
| 2 | TCGA-22-1000-01A-01R-A32Z-07 | — | cohortSQ1 | 0.928 |
| 3 | TCGA-55-6985-01A-11R-1949-07 | — | cohortA1 | 0.927 |
| 4 | TCGA-75-7030-01A-11R-1949-07 | — | cohortA1 | 0.925 |
| 5 | MDT-AP-2743 | Med | Medulloblastoma | 0.923 |
| 6 | 2eaa09cd-8e3e-4de9-ab96-7a290d780a01 | — | — | 0.921 |
| 7 | TCGA-55-6980-01A-11R-1949-07 | — | cohortA1 | 0.919 |
| 8 | SRR4296080 | — | cohortA1 | 0.918 |
| 9 | TCGA-55-7281-01A-11R-2039-07 | — | cohortA1 | 0.918 |
| 10 | TCGA-CR-7393-01A-11R-2016-07 | — | — | 0.917 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.550 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.490 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.460 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.460 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.430 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.390 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.380 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.380 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.360 | Temsirolimus | — uncovered |
| HEDGEHOG_SIGNALING | 0.360 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.360 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.350 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.350 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.340 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.320 | Inavolisib | — uncovered |
| COAGULATION | 0.310 | Binimetinib | — uncovered |
| ANDROGEN_RESPONSE | 0.300 | Inavolisib | — uncovered |
| MYOGENESIS | 0.300 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.300 | Idelalisib | — uncovered |
| COMPLEMENT | 0.290 | Inavolisib | — uncovered |